regulatory approval Nov 16, 2022 NICE Approves Takeda's Exkivity for EGFR Exon 20 Insertion-Positive NSCLC Nov 15, 2022 FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Aug 22, 2022 Pillar Biosciences Receives China Approval for Colon Cancer Companion Diagnostic Assay Aug 5, 2022 FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer Jul 15, 2022 Pfizer's Xalkori Gets FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors Jun 22, 2022 European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC May 20, 2022 FDA, Industry Look to Congress to Reauthorize User-Fee Act, Improve Cell Therapy Regulation Premium May 13, 2022 NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC Apr 5, 2022 Bristol Myers Squibb's Breyanzi Approved in Europe for Lymphoma Patients Mar 23, 2022 Xcovery's Ensartinib Approved for First-Line ALK-Positive NSCLC in China Mar 15, 2022 Burning Rock Secures Lung Cancer NGS Test Regulatory Approval in China Jan 28, 2022 Pfizer's Lorviqua Approved in EU for First-Line Treatment of ALK-Positive Advanced Lung Cancer Jan 26, 2022 FDA Approves Immunocore's T-Cell Receptor Therapy Kimmtrak for Uveal Melanoma Patients Dec 28, 2021 CStone, Blueprint Medicines' Ayvakit Nets Hong Kong Approval for Biomarker-Defined GIST Nov 19, 2021 European Commission Approves Roche's Gavreto for RET Fusion-Positive NSCLC Oct 22, 2021 European Commission Approves Merck's Keytruda-Chemo Combination for Advanced TNBC Patients Oct 4, 2021 FDA Approves Gilead's Tecartus for Acute Lymphoblastic Leukemia Aug 5, 2021 Pillar Biosciences Receives FDA Approval for OncoReveal Dx Lung and Colon Cancer Assay Jul 22, 2021 NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer